Monace Combi (Fosinopril Sodium, Hydrochlorothiazide)

Fosinopril sodium, the active ingredient in Monace Combi, is an ACE inhibitor presented as a tablet for oral use. It lowers blood pressure in adults with hypertension, often in combination with a thiazide diuretic. GNH USA supplies Monace Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monace Combi is an antihypertensive medication that lowers elevated blood pressure through combined ACE inhibition and diuresis.

Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. Essential hypertension: improves blood‑pressure control when monotherapy is insufficient. Fluid retention with hypertension: adds diuretic effect to manage excess volume and lower pressure.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Persistent dry cough. - Headache. - Increased frequency of urination. - Mild electrolyte disturbances such as low potassium. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Severe dehydration or electrolyte imbalance. - Hyperkalemia leading to cardiac rhythm changes. - Acute kidney injury or sudden rise in serum creatinine. - Marked hypotension causing fainting. - Blood dyscrasias such as neutropenia or agranulocytosis.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess efficacy. - Check renal function and serum electrolytes before and during treatment. - Avoid use in patients with severe renal impairment unless specifically directed. - Use caution in diabetic patients as blood‑glucose levels may change. - Assess for a history of angioedema or hypersensitivity to ACE inhibitors. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Monace Combi may interact with several medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment. - Potassium‑containing supplements or salt substitutes. - Lithium, which may reach toxic levels. - Concurrent use of another ACE inhibitor or ARB. - NSAIDs that can diminish renal protective effects.

Moderate Interactions (Monitor Closely): - Other diuretics that may cause additive electrolyte loss. - Additional antihypertensives leading to excessive blood‑pressure reduction. - Antidiabetic agents that may require dose adjustment. - Rifampin, which can lower fosinopril plasma concentrations. - NSAIDs that may reduce the diuretic effect of hydrochlorothiazide.